Personalized medicine strategy for MPNSTs: using precision oncology on PDOX models to inform tumor boards


Por: Ortega-Bertran, S, Fernández-Rodríguez, J, Magallón-Lorenz, M, Creus-Bachiller, E, Uriarte-Arrazola, I, Mazuelas, H, Garraus, M, Carrió, M, Gel, B, Rovira, C, Alvarez, M, Villanueva, A, Castaneda, A, Salvador, H, Serra, E and Lázaro, C

Publicada: 4 feb 2026
Resumen:
BackgroundMalignant peripheral nerve sheath tumors (MPNSTs) are a heterogeneous group of aggressive soft tissue sarcomas with poor prognosis. Currently there is a lack of effective treatments for MPNSTs. Here, we propose a personalized medicine approach that integrates a precision oncology strategy guided by MPNST genomic analysis, with a functional validation of treatment response in an orthotopic xenograft model (PDOX) derived from the same MPNST.MethodsComprehensive whole genome sequencing analysis was performed in primary MPNSTs, relapses and (in one case) metastases, following disease progression in two independent individuals. Matched MPNST PDOX models were generated by orthotopically implanting tumor fragments near the sciatic nerve of immunodeficient mice. Candidate targeted combination therapies were prioritized based on genomic alterations and tested in vivo in the PDOX models.ResultsThe feasibility of the developed strategy is illustrated for two MPNST patients, one Neurofibromatosis type 1 (NF1) individual that developed two independent MPNSTs and another sporadic MPNST case with multiple metastatic relapses. Genomic analysis revealed a remarkable degree of genomic stability across primary MPNSTs and their successive relapses in each patient, and even metastases in one individual. While based on a small number of cases requiring additional analyses, this finding aligns with previous evidence suggesting a fair genomic conservation throughout tumor evolution. This stability supports the identification of consistent therapeutic vulnerabilities throughout disease progression. Among the therapies tested, co-treatment of MEK inhibitor (MEKi) plus bromodomain inhibitor (BETi) elicited the highest antitumor activity, resulting in approximately 60% tumor volume reduction in the sporadic MPNST PDX model, whose patient has been receiving this therapy for eight months with sustained remission.ConclusionsThis study demonstrates the feasibility and clinical utility of integrating genomic-driven precision oncology with PDOX-based functional testing for MPNSTs. This strategy may support molecular tumor boards (MTBs) in their treatment decisions. The observed genomic stability supports the use of longitudinal tumor profiling to guide treatment, and the success of MEKi+BETi highlights its potential as a combination therapy for MPNSTs.

Filiaciones:
Ortega-Bertran, S:
 Hosp Llobregat, Catalan Inst Oncol, IDIBELL, Hereditary Canc Program,ICO, Lhospitalet De Llobregat, Barcelona, Spain

 IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain

 Univ Barcelona, Doctoral Program Biomed, Barcelona, Spain

Fernández-Rodríguez, J:
 Hosp Llobregat, Catalan Inst Oncol, IDIBELL, Hereditary Canc Program,ICO, Lhospitalet De Llobregat, Barcelona, Spain

 IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 IDIBELL, Mouse lab, SCT, Lhospitalet De Llobregat, Barcelona, Spain

Magallón-Lorenz, M:
 Germans Trias & Pujol Res Inst IGTP, CARE Program, Hereditary Canc Grp, Barcelona, Spain

Creus-Bachiller, E:
 Hosp Llobregat, Catalan Inst Oncol, IDIBELL, Hereditary Canc Program,ICO, Lhospitalet De Llobregat, Barcelona, Spain

 IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain

:
 Germans Trias & Pujol Res Inst IGTP, CARE Program, Hereditary Canc Grp, Barcelona, Spain

:
 Germans Trias & Pujol Res Inst IGTP, CARE Program, Hereditary Canc Grp, Barcelona, Spain

Garraus, M:
 Pediat Canc Ctr Barcelona, Esplugas de Llobregat, Spain

:
 Germans Trias & Pujol Res Inst IGTP, CARE Program, Hereditary Canc Grp, Barcelona, Spain

:
 Germans Trias & Pujol Res Inst IGTP, CARE Program, Hereditary Canc Grp, Barcelona, Spain

 Univ Barcelona UB, Dept Fonaments Clin, Fac Med & Ciencies Salut, Barcelona, Spain

Rovira, C:
 St Joan Deu Barcelona Childrens Hosp, Pathol Dept, Barcelona 08950, Spain

Alvarez, M:
 St Joan Deu Barcelona Childrens Hosp, Pathol Dept, Barcelona 08950, Spain

Villanueva, A:
 IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain

 Catalan Inst Oncol, Procure Program, Lhospitalet De Llobregat, Barcelona, Spain

Castaneda, A:
 Pediat Canc Ctr Barcelona, Esplugas de Llobregat, Spain

Salvador, H:
 Pediat Canc Ctr Barcelona, Esplugas de Llobregat, Spain

:
 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Germans Trias & Pujol Res Inst IGTP, CARE Program, Hereditary Canc Grp, Barcelona, Spain

Lázaro, C:
 Hosp Llobregat, Catalan Inst Oncol, IDIBELL, Hereditary Canc Program,ICO, Lhospitalet De Llobregat, Barcelona, Spain

 IDIBELL, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain
ISSN: 14795876





Journal of Translational Medicine
Editorial
BioMed Central, CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND, Reino Unido
Tipo de documento: Article
Volumen: 24 Número: 1
Páginas:
WOS Id: 001717991400001
ID de PubMed: 41639724
imagen Green Submitted, gold

MÉTRICAS